Last reviewed · How we verify
Erlotinib PO and Vidaza IV
Erlotinib PO and Vidaza IV is a Small molecule drug developed by New Mexico Cancer Research Alliance. It is currently in Phase 1 development.
At a glance
| Generic name | Erlotinib PO and Vidaza IV |
|---|---|
| Sponsor | New Mexico Cancer Research Alliance |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erlotinib PO and Vidaza IV CI brief — competitive landscape report
- Erlotinib PO and Vidaza IV updates RSS · CI watch RSS
- New Mexico Cancer Research Alliance portfolio CI
Frequently asked questions about Erlotinib PO and Vidaza IV
What is Erlotinib PO and Vidaza IV?
Erlotinib PO and Vidaza IV is a Small molecule drug developed by New Mexico Cancer Research Alliance.
Who makes Erlotinib PO and Vidaza IV?
Erlotinib PO and Vidaza IV is developed by New Mexico Cancer Research Alliance (see full New Mexico Cancer Research Alliance pipeline at /company/new-mexico-cancer-research-alliance).
What development phase is Erlotinib PO and Vidaza IV in?
Erlotinib PO and Vidaza IV is in Phase 1.